Drug Information Association (DIA) Annual Meeting

Articles

Fathallah shares his thoughts on the recent DIA 2023 Annual Meeting in Boston, MA.

DIA 2023 Recap: Q&A with DIA President and Global Chief Executive, Marwan Fathallah

Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research. 

Importance of DCTs Moving Forward

Videos

How will AI best be positioned to help safety professionals best utilize their time and resources?

AI and Safety: Finding the Signals that Matter

"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.

Public Misunderstandings Around Clinical Trials

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants. 

When Clinical Trial Professionals Participate in a Study

Jaydev Thakkar, chief operating officer, Biofourmis discusses how Biofourmis got involved with the CancerX Initiative at the 2023 DIA annual meeting in Boston, MA.

DIA 2023: How Did Biofourmis Get Involved with CancerX?

Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

DIA 2023: What is Biofourmis Currently Working on with CancerX?

Jaydev Thakkar, chief operating officer, Biofourmis gives an overview of the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

DIA 2023: What is the CancerX Initiative?

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of the EFGCP eConsent Initiative at the 2023 DIA annual meeting in Boston, MA.

DIA 2023: What is the European Forum GCP eConsent Initiative?

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of eConsent at the 2023 DIA annual meeting in Boston, MA.